Top Markets
#1 MowCat MowCat +49.01%
#2 Derive Derive +24.21%
#3 Audiera Audiera +19.54%
#4 Geodnet Geodnet +16.54%
#5 aPriori aPriori +15.50%
#6 Biconomy Biconomy +14.76%
#7 Cross Cross +14.26%
#8 Humanity Humanity +12.39%
#9 Quack AI Quack AI +11.55%
#10 Palladium Network Palladium Network +10.79%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Silo Pharma, Inc. Silo Pharma, Inc.

Silo Pharma, Inc.

SILO
Rank in Stocks #35574
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm... Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Share Price
$3.29
Last synced: 2026-08-14
Market Cap
$3.71M
Change (1 day)
2.17%
Change (1 year)
-69.11%
Country
US
Trade Silo Pharma, Inc. (SILO)

Category

Healthcare
Operating Margin for Silo Pharma, Inc. (SILO)
Operating Margin as of 2026 TTM: 0.00%
According to Silo Pharma, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Silo Pharma, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.